Interaction Between Inducible Nitric Oxide Synthase and Poly(ADP-ribose) Polymerase in Focal Ischemic Brain Injury
- 1 December 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 35 (12) , 2896-2901
- https://doi.org/10.1161/01.str.0000147042.53659.6c
Abstract
Background and Purpose— Overactivation of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) contributes to ischemic brain injury. Because PARP upregulates proinflammatory genes, we investigated whether inducible nitric oxide synthase (iNOS), a gene involved in the deleterious effects of postischemic inflammation, participates in the mechanisms by which PARP activation contributes to cerebral ischemic injury. Methods— The middle cerebral artery (MCA) was occluded in mice for 20 minutes using an intravascular filament, and injury volume was measured 72 hours later in Nissl-stained brain sections. mRNA expression was assessed in the postischemic brain by the quantitative “real-time” polymerase chain reaction. Results— The PARP inhibitor PJ34 reduced infarct volume and attenuated postischemic iNOS mRNA upregulation by 72%. To determine whether iNOS contributes to the toxicity of PARP, the iNOS inhibitor aminoguanidine was co-administered with PARP inhibitors. Unexpectedly, co-administration of PARP and iNOS inhibitors, or treatment of iNOS-null mice with PARP inhibitors, abrogated the protective effect afforded by iNOS or PARP inhibition alone. The loss of neuroprotection was associated with upregulation of the inflammatory genes iNOS, intercellular adhesion molecule-1, and gp91 phox . Conclusions— The results suggest that iNOS expression contributes to the deleterious effects exerted by PARP activation in cerebral ischemia. However, iNOS activity is required for the protective effect of PARP inhibition and, conversely, PARP activity must be present for iNOS inhibition to be effective. The findings unveil a previously unrecognized deleterious interaction between iNOS and PARP that is relevant to the development of combination therapies for ischemic stroke.Keywords
This publication has 24 references indexed in Scilit:
- The Therapeutic Effects of PJ34 [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a Selective Inhibitor of Poly(ADP-Ribose) Polymerase, in Experimental Allergic Encephalomyelitis Are Associated with ImmunomodulationThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Cerebral Microvascular Responses to HypercholesterolemiaCirculation Research, 2004
- Poly(ADP‐ribose) polymerase‐1 activity promotes NF‐κB‐driven transcription and microglial activation: implication for neurodegenerative disordersJournal of Neurochemistry, 2003
- Toward Wisdom From FailureStroke, 2002
- PARP-1--a Perpetrator of Apoptotic Cell Death?Science, 2002
- Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing FactorScience, 2002
- Beneficial Effects Of GPI 6150, an Inhibitor of Poly(ADP-Ribose) Polymerase in a Rat Model of Splanchnic Artery Occlusion and ReperfusionShock, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- The Cyclooxygenase-2 Inhibitor NS-398 Ameliorates Ischemic Brain Injury in Wild-Type Mice but not in Mice with Deletion of the Inducible Nitric Oxide Synthase GeneJournal of Cerebral Blood Flow & Metabolism, 1999
- Delayed Treatment with Aminoguanidine Decreases Focal Cerebral Ischemic Damage and Enhances Neurologic Recovery in RatsJournal of Cerebral Blood Flow & Metabolism, 1998